Ronald King

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Pluristyx secures a key Japanese patent for its rapid mRNA reprogramming tech, slashing iPSC production time and promising to unlock commercial-scale cell therapy.

A new survey reveals an overwhelming public demand to treat epinephrine like defibrillators. This isn't just about allergies; it's a systemic shift in our definition of public safety.

Mission 300 has connected 50 million Africans to power, but the real story is the systemic blueprint behind it: a powerful new model for global development.

Enterprises are stuck between rapid AI prototyping and the slow, necessary grind of governance. Dataiku's new AI agent, Cobuild, promises to unite them.

MedPro Healthcare Staffing's seventh consecutive Top Workplace award isn't just a trophy; it's a strategic asset in the war for talent. But what does it mean?

Phil McCabe, the man who built modern Naples, just made a $20M+ purchase at the new Four Seasons. It’s more than a home—it’s a signal about the future of luxury capital.

New research reveals some AI-generated customer data leads to false conclusions 60% of the time. Here's the framework investors need to separate fact from fiction.

The Object Management Group is standardizing Rust with its IDL4 framework, a move set to accelerate the language's adoption in critical enterprise systems.

CEO Emun Zabihi’s EY award isn’t just a personal victory. It’s a signal that iHerb has perfected the digital and physical infrastructure for global wellness.

New data reveals upstream patient guidance slashes surgical costs, challenging the old guard of healthcare management and signaling a new era of digital-first care.

A US food-tech innovator and a Bulgarian industrial giant are quadrupling animal-free egg protein production, signaling a tectonic shift in global supply chains.

With its acquisitions of Orosound and AudioSourceRE, Syntiant isn't just buying tech; it's building a vertically integrated empire for on-device AI.

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

Gilat's acquisition of a key Comtech division isn't just a purchase; it's a strategic power play to build a $700M defense tech giant for a new era.

Dr. Aida Habtezion’s leap from Pfizer to the board of Bio Usawa is more than a career move; it’s a key signal in the race to build Africa’s medical independence.

ING elevates its HR chief to the management board, a strategic bet that human capital, not just financial capital, will define the future of banking.

Jinan's 'City of Springs' promotion in Madrid is more than cultural outreach; it’s a blueprint for China's new economic statecraft in Europe.

FCPT's latest acquisition seems minor, but it reveals a powerful strategy for navigating economic uncertainty by targeting essential, service-based real estate.

AIFU, a Chinese fintech firm on the brink, plans to acquire a waste-tech AI company. Is this a visionary leap into green industry or a desperate gamble?